E
Eva Gimeno
Researcher at Autonomous University of Barcelona
Publications - 48
Citations - 818
Eva Gimeno is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Lymphoma & Chronic lymphocytic leukemia. The author has an hindex of 14, co-authored 48 publications receiving 580 citations. Previous affiliations of Eva Gimeno include University of Perugia.
Papers
More filters
Journal ArticleDOI
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò,Thomas Chatzikonstantinou,Gian Matteo Rigolin,Giulia Quaresmini,Marina Motta,Candida Vitale,José A. García-Marco,Jose Angel Hernandez-Rivas,Fatima Miras,Mónica Baile,Juan Marquet,Carsten Utoft Niemann,Gianluigi Reda,Talha Munir,Eva Gimeno,Monia Marchetti,Francesca Maria Quaglia,Marzia Varettoni,Julio Delgado,Sunil Iyengar,Ann Janssens,Roberto Marasca,Angela Ferrari,Carolina Cuéllar-García,Gilad Itchaki,Martin Spacek,Lorenzo De Paoli,Luca Laurenti,Mark-David Levin,Enrico Lista,Francesca Romana Mauro,Martin Simkovic,Ellen van der Spek,Elisabeth Vandenberghe,Livio Trentin,Ewa Wasik-Szczepanek,Rosa Ruchlemer,Dominique Bron,Maria Rosaria De Paolis,Giovanni Del Poeta,Lucia Farina,Myriam Foglietta,Massimo Gentile,Yair Herishanu,Tobias Herold,Ozren Jakšić,Arnon P. Kater,Sabina Kersting,Lara Malerba,Lorella Orsucci,Viola Maria Popov,Paolo Sportoletti,Mohamed A. Yassin,Barbara Pocali,Gábor Barna,Annalisa Chiarenza,Gimena Dos Santos,Eugene Nikitin,Martin Andres,Maria Dimou,Michael Doubek,Alicia Enrico,Yervand K Hakobyan,Olga Kalashnikova,Macarena Ortiz Pareja,Maria Papaioannou,Davide Rossi,Nimish Shah,Amit Shrestha,Oana Stanca,Niki Stavroyianni,Vladimir Strugov,Constantine S. Tam,Mihnea Zdrenghea,Marta Coscia,Kostas Stamatopoulos,Giuseppe Rossi,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Paolo Ghia +81 more
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Journal ArticleDOI
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Pier Paolo Piccaluga,Andrea Califano,Ulf Klein,Claudio Agostinelli,Beatriz Bellosillo,Eva Gimeno,Sergi Serrano,Francisco Solè,Yonghui Zang,Brunangelo Falini,Pier Luigi Zinzani,Stefano Pileri +11 more
TL;DR: The findings of this study support the hypothesis that grade IIIb follicular lymphoma belongs to the group of follicles lymphomas rather than to diffuse large B-cell lymphomas and suggest a possible revision of the histological grading of follicle lymphomas.
Journal ArticleDOI
MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma
Concepción Fernández-Rodríguez,Beatriz Bellosillo,Mar Garcia-Garcia,Blanca Sanchez-Gonzalez,Eva Gimeno,Maria Carmen Vela,Sergi Serrano,Carlos Besses,Antonio Salar +8 more
TL;DR: MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.
Journal ArticleDOI
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients
Alberto Alvarez-Larrán,Beatriz Bellosillo,Luz Martínez-Avilés,Silvia Saumell,Antonio Salar,Eugenia Abella,Eva Gimeno,Sergi Serrano,Lourdes Florensa,Blanca Sánchez,Carmen Pedro,Carles Besses +11 more
TL;DR: PPMF is a frequent complication in PV patients at 15’years with the risk being higher in patients with increased LDH, endogenous megakaryocytic colony formation or a high JAK2 V617F allele burden.
Journal ArticleDOI
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Thomas Chatzikonstantinou,Anargyros Kapetanakis,Lydia Scarfò,Georgios Karakatsoulis,David Allsup,Alejandro Alonso Cabrero,Martin Andres,Darko Antic,Mónica Baile,Panagiotis Baliakas,Panagiotis Baliakas,Dominique Bron,Antonella Capasso,Sofia Chatzileontiadou,Raul Cordoba,Juan-Gonzalo Correa,Carolina Cuéllar-García,Lorenzo De Paoli,Maria Rosaria De Paolis,Giovanni Del Poeta,Christos Demosthenous,Maria Dimou,David Donaldson,Michael Doubek,Maria Efstathopoulou,Barbara Eichhorst,Shaimaa El-Ashwah,Alicia Enrico,Blanca Espinet,Lucia Farina,Angela Ferrari,Myriam Foglietta,Henrik Frederiksen,Moritz Fürstenau,José A. García-Marco,Rocío García-Serra,Massimo Gentile,Eva Gimeno,Andreas Glenthøj,Maria Gomes da Silva,Odit Gutwein,Yervand K Hakobyan,Yair Herishanu,Jose Angel Hernandez-Rivas,Tobias Herold,Idanna Innocenti,Gilad Itchaki,Ozren Jakšić,Ann Janssens,Оlga B Kalashnikova,Elżbieta Kalicińska,Linda Katharina Karlsson,Arnon P. Kater,Sabina Kersting,Jorge Labrador,Deepesh Lad,Luca Laurenti,Luca Laurenti,Mark-David Levin,Enrico Lista,Alberto Lopez-Garcia,Lara Malerba,Roberto Marasca,Monia Marchetti,Juan Marquet,Mattias Mattsson,Mattias Mattsson,Francesca Romana Mauro,Ivana Milosevic,Fatima Miras,Marta Morawska,Marta Morawska,Marina Motta,Talha Munir,Roberta Murru,Carsten Utoft Niemann,Raquel Nunes Rodrigues,Jacopo Olivieri,Lorella Orsucci,Maria Papaioannou,Miguel Arturo Pavlovsky,Inga Piskunova,Viola Maria Popov,Francesca Maria Quaglia,Giulia Quaresmini,Kristian Qvist,Gianluigi Reda,Gian Matteo Rigolin,Rosa Ruchlemer,Gevorg Saghumyan,Amit Shrestha,Martin Simkovic,Martin Spacek,Paolo Sportoletti,Oana Stanca,Niki Stavroyianni,Tamar Tadmor,Doreen te Raa,Sanne H. Tonino,Livio Trentin,Ellen van der Spek,Michel van Gelder,Roel van Kampen,Marzia Varettoni,Andrea Visentin,Candida Vitale,Ewa Wasik-Szczepanek,Tomasz Wróbel,Lucrecia Yáñez San Segundo,Mohamed A. Yassin,Marta Coscia,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Kostas Stamatopoulos,Paolo Ghia +116 more
TL;DR: In this paper, the authors investigated the impact of CLL-directed treatments on the course of Coronavirus disease 2019 (COVID-19) and found that patients with chronic lymphocytic leukemia (CLL) may be more susceptible to the disease due to age, disease, and treatment-related immunosuppression.